The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Remicade (Infliximab) Monoclonal Antibody Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029
Synopsis
The global Remicade (Infliximab) Monoclonal Antibody market size was valued at USD 2623.8 million in 2022 and is forecast to a readjusted size of USD 3781.3 million by 2029 with a CAGR of 5.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
This report is a detailed and comprehensive analysis for global Remicade (Infliximab) Monoclonal Antibody market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Remicade (Infliximab) Monoclonal Antibody market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Remicade (Infliximab) Monoclonal Antibody market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Remicade (Infliximab) Monoclonal Antibody market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Remicade (Infliximab) Monoclonal Antibody market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Remicade (Infliximab) Monoclonal Antibody
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Remicade (Infliximab) Monoclonal Antibody market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include J & J, Pfizer, Organon and Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Remicade (Infliximab) Monoclonal Antibody market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Brand
Biosimilar
Market segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Major players covered
J & J
Pfizer
Organon
Amgen
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Remicade (Infliximab) Monoclonal Antibody product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Remicade (Infliximab) Monoclonal Antibody, with price, sales, revenue and global market share of Remicade (Infliximab) Monoclonal Antibody from 2018 to 2023.
Chapter 3, the Remicade (Infliximab) Monoclonal Antibody competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Remicade (Infliximab) Monoclonal Antibody breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Remicade (Infliximab) Monoclonal Antibody market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Remicade (Infliximab) Monoclonal Antibody.
Chapter 14 and 15, to describe Remicade (Infliximab) Monoclonal Antibody sales channel, distributors, customers, research findings and conclusion.
The global Remicade (Infliximab) Monoclonal Antibody market size was valued at USD 2623.8 million in 2022 and is forecast to a readjusted size of USD 3781.3 million by 2029 with a CAGR of 5.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
This report is a detailed and comprehensive analysis for global Remicade (Infliximab) Monoclonal Antibody market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Remicade (Infliximab) Monoclonal Antibody market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Remicade (Infliximab) Monoclonal Antibody market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Remicade (Infliximab) Monoclonal Antibody market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Remicade (Infliximab) Monoclonal Antibody market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Remicade (Infliximab) Monoclonal Antibody
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Remicade (Infliximab) Monoclonal Antibody market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include J & J, Pfizer, Organon and Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Remicade (Infliximab) Monoclonal Antibody market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Brand
Biosimilar
Market segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Major players covered
J & J
Pfizer
Organon
Amgen
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Remicade (Infliximab) Monoclonal Antibody product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Remicade (Infliximab) Monoclonal Antibody, with price, sales, revenue and global market share of Remicade (Infliximab) Monoclonal Antibody from 2018 to 2023.
Chapter 3, the Remicade (Infliximab) Monoclonal Antibody competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Remicade (Infliximab) Monoclonal Antibody breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Remicade (Infliximab) Monoclonal Antibody market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Remicade (Infliximab) Monoclonal Antibody.
Chapter 14 and 15, to describe Remicade (Infliximab) Monoclonal Antibody sales channel, distributors, customers, research findings and conclusion.
Index1 Market Overview
1.1 Product Overview and Scope of Remicade (Infliximab) Monoclonal Antibody
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Brand
1.3.3 Biosimilar
1.4 Market Analysis by Application
1.4.1 Overview: Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Ankylosing Spondylitis
1.4.3 Rheumatoid Arthritis
1.4.4 Crohn’s Disease
1.4.5 Other
1.5 Global Remicade (Infliximab) Monoclonal Antibody Market Size & Forecast
1.5.1 Global Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity (2018-2029)
1.5.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price (2018-2029)
2 Manufacturers Profiles
2.1 J & J
2.1.1 J & J Details
2.1.2 J & J Major Business
2.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Product and Services
2.1.4 J & J Remicade (Infliximab) Monoclonal Antibody Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 J & J Recent Developments/Updates
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Product and Services
2.2.4 Pfizer Remicade (Infliximab) Monoclonal Antibody Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer Recent Developments/Updates
2.3 Organon
2.3.1 Organon Details
2.3.2 Organon Major Business
2.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Product and Services
2.3.4 Organon Remicade (Infliximab) Monoclonal Antibody Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Organon Recent Developments/Updates
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Product and Services
2.4.4 Amgen Remicade (Infliximab) Monoclonal Antibody Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Amgen Recent Developments/Updates
3 Competitive Environment: Remicade (Infliximab) Monoclonal Antibody by Manufacturer
3.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Manufacturer (2018-2023)
3.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Manufacturer (2018-2023)
3.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Remicade (Infliximab) Monoclonal Antibody by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Remicade (Infliximab) Monoclonal Antibody Manufacturer Market Share in 2022
3.4.2 Top 6 Remicade (Infliximab) Monoclonal Antibody Manufacturer Market Share in 2022
3.5 Remicade (Infliximab) Monoclonal Antibody Market: Overall Company Footprint Analysis
3.5.1 Remicade (Infliximab) Monoclonal Antibody Market: Region Footprint
3.5.2 Remicade (Infliximab) Monoclonal Antibody Market: Company Product Type Footprint
3.5.3 Remicade (Infliximab) Monoclonal Antibody Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Remicade (Infliximab) Monoclonal Antibody Market Size by Region
4.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2018-2029)
4.1.2 Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2018-2029)
4.1.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2018-2029)
4.2 North America Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)
4.3 Europe Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)
4.4 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)
4.5 South America Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)
4.6 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)
5.2 Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Type (2018-2029)
5.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)
6.2 Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Application (2018-2029)
6.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2018-2029)
7 North America
7.1 North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)
7.2 North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)
7.3 North America Remicade (Infliximab) Monoclonal Antibody Market Size by Country
7.3.1 North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2029)
7.3.2 North America Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)
8.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)
8.3 Europe Remicade (Infliximab) Monoclonal Antibody Market Size by Country
8.3.1 Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2029)
8.3.2 Europe Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Market Size by Region
9.3.1 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)
10.2 South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)
10.3 South America Remicade (Infliximab) Monoclonal Antibody Market Size by Country
10.3.1 South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2029)
10.3.2 South America Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Market Size by Country
11.3.1 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Remicade (Infliximab) Monoclonal Antibody Market Drivers
12.2 Remicade (Infliximab) Monoclonal Antibody Market Restraints
12.3 Remicade (Infliximab) Monoclonal Antibody Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Remicade (Infliximab) Monoclonal Antibody and Key Manufacturers
13.2 Manufacturing Costs Percentage of Remicade (Infliximab) Monoclonal Antibody
13.3 Remicade (Infliximab) Monoclonal Antibody Production Process
13.4 Remicade (Infliximab) Monoclonal Antibody Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Remicade (Infliximab) Monoclonal Antibody Typical Distributors
14.3 Remicade (Infliximab) Monoclonal Antibody Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
